A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 40M | 40M | 41M | 30M | 32M | 27M |
| Net Income | 5.9M | 5.9M | 4.3M | -494K | 2.9M | -10M |
| EPS | $0.13 | $0.13 | $0.10 | $-0.01 | $0.07 | $-0.23 |
| Free Cash Flow | 10M | 10M | 8.6M | -1.1M | 1.6M | -16M |
| ROIC | 22.4% | 21.5% | 17.1% | -1.7% | 11.5% | 16.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.04 | 0.03 | 0.06 | 0.06 | 0.06 |
| Dividends/Share | $0.16 | $0.16 | - | - | $0.06 | $0.11 |
| Operating Income | 8.0M | 8.0M | 6.5M | -638K | 3.9M | 4.9M |
| Operating Margin | 19.9% | 19.9% | 15.8% | -2.1% | 12.1% | 18.0% |
| ROE | 20.3% | 19.7% | 14.6% | -1.6% | 9.5% | -35.6% |
| Shares Outstanding | 44M | 44M | 44M | 43M | 44M | 44M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 27M | 32M | 30M | 41M | 40M | 40M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 4.9M | 3.9M | -638K | 6.5M | 8.0M | 8.0M |
| Op. Margin | 18.0% | 12.1% | -2.1% | 15.8% | 19.9% | 19.9% |
| Net Income | -10M | 2.9M | -494K | 4.3M | 5.9M | 5.9M |
| Net Margin | -38.3% | 9.0% | -1.6% | 10.5% | 14.6% | 14.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 16.7% | 11.5% | -1.7% | 17.1% | 21.5% | 22.4% |
| ROE | -35.6% | 9.5% | -1.6% | 14.6% | 19.7% | 20.3% |
| ROA | -30.1% | 7.9% | -1.2% | 10.7% | 15.8% | 16.3% |
| Cash Flow | ||||||
| Op. Cash Flow | -16M | 1.6M | -1.1M | 8.6M | 10M | 10M |
| Free Cash Flow | -16M | 1.6M | -1.1M | 8.6M | 10M | 10M |
| Owner Earnings | -17M | 358K | -2.4M | 7.0M | 8.3M | 8.3M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 1.0M | 1.2M | 1.3M | 1.6M | 1.8M | 1.8M |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 1.0M | 1.2M | 1.3M | 1.6M | 1.8M | 1.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 4.7M | 2.6M | 0 | 0 | 7.3M | 7.3M |
| Dividend Yield | 7.8% | 2.3% | N/A | N/A | 7.4% | 0.7% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -6.4M | -2.3M | 1.5M | -1.4M | -126K | -1.2M |
| Cash & Equiv. | 8.2M | 4.2M | 150K | 2.5M | 1.2M | 1.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.06 | 0.06 | 0.06 | 0.03 | 0.04 | 0.00 |
| Interest Coverage | 0.2 | 4.5 | -0.6 | 2.2 | 5.9 | 5.9 |
| Equity | 29M | 32M | 29M | 31M | 29M | 29M |
| Total Assets | 34M | 39M | 43M | 38M | 36M | 36M |
| Total Liabilities | 5.3M | 6.7M | 14M | 7.7M | 7.1M | 7.1M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -106K | 2.9M | 2.3M | 6.8M | 13M | 13M |
| Working Capital | 12M | 11M | 4.4M | 9.4M | 7.4M | 7.4M |
| Current Assets | 15M | 16M | 17M | 16M | 13M | 13M |
| Current Liabilities | 3.4M | 4.8M | 12M | 6.6M | 6.0M | 6.0M |
| Per Share Data | ||||||
| EPS | -0.23 | 0.07 | -0.01 | 0.10 | 0.13 | 0.13 |
| Owner EPS | -0.37 | 0.01 | -0.06 | 0.16 | 0.19 | 0.19 |
| Book Value | 0.66 | 0.72 | 0.67 | 0.69 | 0.66 | 0.66 |
| Cash Flow/Share | -0.35 | 0.04 | -0.03 | 0.19 | 0.23 | 0.17 |
| Dividends/Share | 0.11 | 0.06 | N/A | N/A | 0.16 | 0.16 |
| Shares Out. | 44.3M | 44.4M | 42.9M | 44.3M | 44.2M | 44.2M |
| Valuation | ||||||
| P/E Ratio | -8.7 | 29.0 | -142.0 | 23.4 | 15.9 | 167.7 |
| P/FCF | N/A | 52.7 | N/A | 11.8 | 9.2 | 97.6 |
| EV/EBIT | 17.3 | 21.1 | N/A | 15.4 | 11.7 | 123.3 |
| Price/Book | 3.1 | 2.6 | 2.4 | 3.3 | 3.2 | 34.0 |
| Price/Sales | 3.4 | 2.6 | 2.3 | 2.5 | 2.3 | 24.5 |
| FCF Yield | -17.2% | 1.9% | -1.6% | 8.5% | 10.8% | 1.0% |
| Market Cap | 91M | 84M | 70M | 101M | 93M | 985M |
| Avg. Price | 1.37 | 2.53 | 1.71 | 2.01 | 2.21 | 22.30 |
| Year-End Price | 2.05 | 1.89 | 1.64 | 2.29 | 2.11 | 22.30 |
VISTIN PHARMA passes 3 of 9 quality checks, indicating weak fundamentals.
VISTIN PHARMA trades at 167.8x trailing earnings, compared to its 15-year median P/E of 23.4x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 97.6x vs a median of 11.8x. The company's 5-year average ROIC is 13.0%. Total shareholder yield (dividends) is 0.7%. At current prices, the estimated annualized return to fair value is +87.4%.
VISTIN PHARMA (VISTN-OL) has a current P/E ratio of 167.8, compared to its historical median P/E of 23.4. The stock is currently considered Expensive based on its historical valuation range.
VISTIN PHARMA (VISTN-OL) has a 5-year average return on invested capital (ROIC) of 13.0%. This indicates solid capital allocation.
VISTIN PHARMA (VISTN-OL) has a market capitalization of $985M. It is classified as a small-cap stock.
Yes, VISTIN PHARMA (VISTN-OL) pays a dividend with a trailing twelve-month yield of 0.74%.
Based on historical P/E analysis, VISTIN PHARMA (VISTN-OL) appears expensive. The current P/E of 167.8 is 616% above its historical median of 23.4. The estimated fair value CAGR (P/E method) is 25.7%.
VISTIN PHARMA (VISTN-OL) reported annual revenue of $40 million in its most recent fiscal year, based on SEC EDGAR filings.
VISTIN PHARMA (VISTN-OL) has a net profit margin of 14.6%. This is a healthy margin.
VISTIN PHARMA (VISTN-OL) generated $10 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
VISTIN PHARMA (VISTN-OL) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
VISTIN PHARMA (VISTN-OL) reported earnings per share (EPS) of $0.13 in its most recent fiscal year.
VISTIN PHARMA (VISTN-OL) has a return on equity (ROE) of 19.7%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 5 years of financial data for VISTIN PHARMA (VISTN-OL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VISTIN PHARMA (VISTN-OL) has a book value per share of $0.66, based on its most recent annual SEC filing.
No recent items.